Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches

Radiat Oncol. 2018 May 23;13(1):98. doi: 10.1186/s13014-018-1037-7.

Abstract

Prostate Cancer is the forth most common type of cancer. Prostate-specific membrane antigen (PSMA) is anchored in the cell membrane of prostate epithelial cells. PSMA is highly expressed on prostate epithelial cells and strongly up-regulated in prostate cancer. Therefore it is an appropriate target for diagnostic and therapy of prostate cancer and its metastases. This article discusses several articles on radionuclide treatments in prostate cancer and the results on PSMA therapy with either beta or alpha emitters as a salvage therapy.

Keywords: Metastatic disease; PSMA; Prostate cancer; Radioligand therapy.

Publication types

  • Review

MeSH terms

  • Antigens, Surface / metabolism*
  • Glutamate Carboxypeptidase II / metabolism*
  • Humans
  • Male
  • Neoplasm Metastasis
  • Practice Patterns, Physicians'*
  • Prognosis
  • Prostatic Neoplasms, Castration-Resistant / metabolism
  • Prostatic Neoplasms, Castration-Resistant / radiotherapy*
  • Prostatic Neoplasms, Castration-Resistant / secondary*
  • Radiopharmaceuticals / therapeutic use*

Substances

  • Antigens, Surface
  • Radiopharmaceuticals
  • FOLH1 protein, human
  • Glutamate Carboxypeptidase II